Brokerages Set Stoke Therapeutics, Inc. (NASDAQ:STOK) PT at $20.83

Stoke Therapeutics, Inc. (NASDAQ:STOK) has been given a consensus recommendation of “Buy” by the nine brokerages that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $20.83.

A number of equities analysts have recently commented on the stock. Leerink Partnrs raised shares of Stoke Therapeutics to a “strong-buy” rating in a research report on Friday, October 11th. Leerink Partners assumed coverage on Stoke Therapeutics in a report on Monday, October 14th. They set an “outperform” rating and a $18.00 price objective on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a report on Wednesday, November 6th. Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. Finally, HC Wainwright restated a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, November 6th.

Insider Buying and Selling

In other Stoke Therapeutics news, insider Barry Ticho sold 2,586 shares of Stoke Therapeutics stock in a transaction on Monday, December 9th. The shares were sold at an average price of $12.99, for a total value of $33,592.14. Following the transaction, the insider now directly owns 44,746 shares of the company’s stock, valued at approximately $581,250.54. The trade was a 5.46 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Skorpios Trust sold 1,937,500 shares of the company’s stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $14.05, for a total value of $27,221,875.00. Following the transaction, the insider now directly owns 8,906,181 shares in the company, valued at approximately $125,131,843.05. The trade was a 17.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 2,000,349 shares of company stock worth $28,031,296 in the last three months. 11.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Stoke Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Quest Partners LLC purchased a new position in shares of Stoke Therapeutics in the second quarter worth $29,000. Nisa Investment Advisors LLC increased its holdings in shares of Stoke Therapeutics by 53.2% in the second quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock valued at $40,000 after purchasing an additional 1,038 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Stoke Therapeutics in the second quarter worth about $123,000. Intech Investment Management LLC acquired a new stake in shares of Stoke Therapeutics during the third quarter worth about $160,000. Finally, The Manufacturers Life Insurance Company boosted its position in Stoke Therapeutics by 16.7% in the second quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock valued at $189,000 after buying an additional 1,994 shares during the last quarter.

Stoke Therapeutics Stock Down 2.1 %

STOK opened at $12.06 on Thursday. The business has a fifty day moving average of $12.49 and a 200 day moving average of $13.64. The stock has a market cap of $638.82 million, a P/E ratio of -5.74 and a beta of 0.95. Stoke Therapeutics has a 52-week low of $4.09 and a 52-week high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last issued its earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.05. The firm had revenue of $4.89 million during the quarter, compared to analyst estimates of $3.46 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. Equities analysts anticipate that Stoke Therapeutics will post -2.03 EPS for the current fiscal year.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.